With the recent Hemlibra approval and the gene therapy revolution, we are seeing a much-needed race to innovate more effective, long-lasting and curative therapies for hemophilia and acquired bleeding disorders.
As such, the 3rd Hemophilia Drug Development Summit is going digital and remains dedicated to bringing to patients more effective commercially and clinically translated therapies from small molecules to gene therapies to improve patients’ quality of life.
Bringing together over 100 of the world’s leading experts and drug developers, we discuss how to develop new therapies for a responsive subset of hemophiliac patients, optimize clinical trial development (setup and management) and discuss the patient/payer paradigm to ensure these novel therapies are affordable and accessible.
Brought directly to your home office with a jam-packed agenda and online virtual networking opportunities, this exclusive virtual summit will delve into the challenges of treating each patient subset, as well as hearing the latest advancements in gene therapy and discussing the critical hurdles that need to be overcome to meet the unmet clinical need of all patients.
Join us as we unite drug developers and researchers on a dedicated online platform and look to the innovation driving the field towards more long-acting and curative therapies to improve patient quality of life.
Drug Developer - Conference Only – Early bird rates available: USD 1249.00,
Academic - Conference Only – Early bird rates available: USD 829.00,
Solution Provider - Conference Only – Early bird rates available: USD 1549.00
Speakers: David Wraith, Institute Director and Professor of Immunology, University of Birmingham Chief Scientific Officer, Apitope, Oscar Segurado, Chief Medical Officer, ASC Therapeutics, Keith Life Senior Director, Gene Therapy Manufacturing, BioMarin, Jonathan Roberts, Associate Director - Medical and Research and Assistant Professor of Pediatrics, Bleeding and Clotting Disorders Institute, Brahm Goldstein, Executive Director and Global Therapeutic Area Head, Hematology, Clinical Research and Development, CSL Behring, Robert Sidonio, Assistant Professor, Emory University, Mark Plencner, Director, Payer Relations, Hemophilia Alliance, John Murphy, Vice President, Discovery Biology, Rare Disease Research Unit, Pfizer, Devyn Smith, Chief Operating Officer, Sigilon Therapeutics, Eileen Sawyer, Vice President, Global Medical Affairs, uniQure, Inc, Robert Kotin, Adjunct Professor, University of Massachusetts, Angela Weyand, Assistant Professor, University of Michigan
Time: 08.30 am - 07:00 pm